- PII
- S2686738925010056-1
- DOI
- 10.31857/S2686738925010056
- Publication type
- Article
- Status
- Published
- Authors
- Volume/ Edition
- Volume 520 / Issue number 1
- Pages
- 26-30
- Abstract
- The efficacy of poloxamer 188 on medullary hematopoiesis in aplastic anemia was investigated. The present study demonstrated that poloxamer 188 at doses of 10 mg/kg, 100 mg/kg and 500 mg/kg administered via oral gavage in CBA mice, in the context of the development of anemia, a dose-dependent effect was observed, characterized by an increase in erythrocyte, hemoglobin and reticulocyte numbers. In the group with carboplatin, these parameters were decreased on day 21, indicating mild anemia. It has been established that P188 has the capacity to exert a beneficial influence on the blood cell composition, which is disrupted by cytostatic drugs.
- Keywords
- полоксамер 188 апластическая анемия мыши CBA
- Date of publication
- 15.09.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 18
References
- 1. Chen W.N., Shaikh M.F., Bhuvanendran S., et al. Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review // Curr Neuropharmacol. 2022. Vol. 20, N4. P. 799–808.
- 2. Ruhl T., Storti G., Pallua N. Proliferation, Metabolic Activity, and Adipogenic Differentiation of Human Preadipocytes Exposed to 2 Surfactants In Vitro // J Pharm Sci. 2018. Vol. 107, N5. P. 1408–1415.
- 3. Moloughney J.G., Weisleder N. Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications // Recent Pat Biotechnol. 2012. Vol. 6, N3. P. 200–11.
- 4. Zylke J. Poloxamer 188 for Sickle Cell Disease // JAMA. 2021. Vol. 325, N 15. P. 1524.
- 5. Gibbs W.J., Hagemann T.M. Purified poloxamer 188 for sickle cell vaso-occlusive crisis // Ann Pharmacother. 2004. Vol. 38, N2. P. 320–324.
- 6. Аршинцева Е.В., Пушкин С.Ю. Новое применение полоксамера в качестве фармакологически активного вещества. Патент РФ № 2 760 324. 2021.11.24.
- 7. Moore C. A., Krishnan K. Aplastic Anemia. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
- 8. Dygai A.M., Zyuz’kov G.N., Zhdanov V.V., et al. Mechanisms underlying modulation of the pharmacological properties of pegylated erythropoietin by pegylated hyaluronate-endo-β-N-acetylhexosaminidase // Bull Exp Biol Med. 2013. Vol. 154, N6. P. 750–4.
- 9. BASF NA Product Regulations. Safety Data Sheet Kolliphor® P 188 Geismar; 2020.
- 10. Wang J.B., Du M.W., Zheng Y. Effect of ginsenoside Rg1 on hematopoietic stem cells in treating aplastic anemia in mice via MAPK pathway // World J Stem Cells. 2024. Vol. 16, N5. P. 591–603.
- 11. Sandor B., Marin M., Lapoumeroulie C., et al. Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia // Br J Haematol. 2016. Vol. 173, N1. P. 145–149.
- 12. Crawford J., Herndon D., Gmitter K., et al. The impact of myelosuppression on quality of life of patients treated with chemotherapy // Future Oncol. 2024. P. 1–16.
- 13. Zhang Y., Tang L., Sun L., et al. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment // Acta Biomater. 2010. Vol. 6, N6. P. 2045–2052.
